Amanta Healthcare IPO Subscription Skyrockets to 59x as Bidding Ends Today; GMP Hints at Moderate Listing Gain

The Amanta Healthcare IPO will close the bidding window today, September 3rd, after experiencing a tremendous surge in investor interest in the IPO over the three-day subscription period. The public issue has been subscribed to nearly 59 times overall, with massive demand across investor categories.

Amanta Healthcare IPO Subscription

According to data from BSE, investor participation has been particularly impressive, with the retail category oversubscribed by more than 45 times. Qualified Institutional Buyers (QIBs), excluding anchor investors, have subscribed nearly 12 times, while Non-Institutional Investors (NIIs) have led the demand with an extraordinary subscription of over 153 times as of mid-afternoon on the final day of the bidding process.

Amanta Healthcare IPO Details and GMP

Priced within a band of Rs. 120 to Rs. 126 per share, the fresh issue comprises 1 crore shares, totalling a market offering size of Rs. 126 crore. According to the current data from the InvestorGain website. The current grey market premium (GMP) stands at Rs. 8, indicating an anticipated listing price of around Rs. 134 per share. This suggests an estimated gain of approximately 6.35% for investors subscribing at the upper end of the price band.

The IPO subscription opened on September 1 and concludes today, with the allotment expected to be finalised promptly on September 4. Tentative plans have set the listing date on the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) for September 9.

A brokerage firm, Minerva Capital Research Solutions, suggested a "May Subscribe" rating for the Amanta Healthcare IPO, citing several positive factors balanced against some risks. "The company has an established market position with extensive manufacturing experience and a strong product portfolio spanning multiple therapeutic segments. Planned capacity expansions in high-value segments like Steriport and Small Volume Parenterals are expected to drive future growth and potentially improve margins. However, concerns remain over the company's relatively high debt-to-equity ratio, exposure to fluctuations in raw material prices linked to crude oil, and ongoing regulatory/legal overhangs," the report read.

Usage of the IPO Proceeds & About Amanta Healthcare Ltd

Amanta Healthcare focuses on manufacturing sterile liquid products, including essential parenteral formulations like intravenous fluids and respiratory care medications. The net proceeds from the IPO are intended to fund capital expenditures aimed at expanding production capacity for existing and new product lines such as SteriPort and small-volume parenterals, as well as general corporate purposes.

Disclaimer: The views and recommendations expressed are solely those of the individual analysts or entities and do not reflect the views of Goodreturns.in or Greynium Information Technologies Private Limited (together referred as "we"). We do not guarantee, endorse or take responsibility for the accuracy, completeness or reliability of any content, nor do we provide any investment advice or solicit the purchase or sale of securities. All information is provided for informational and educational purposes only and should be independently verified from licensed financial advisors before making any investment decisions.